Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
2型真性糖尿病のSitagliptin（DPP-4抑制薬）-によって誘発された関節リウマチ：症例報告。
2012-08-01
Intern Med. 2012; 51; 2041-4;
Kobe University Graduate School of Medicine, Japan. yoyochibiakiko@yahoo.co.jp
Abstract
A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor. The shared epitope (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive. RA might have been triggered by sitagliptin due to a predisposing condition.
我々は、sitagliptin（DPP-4抑制薬）で3ヵ月の治療の最高86IU/mL後に連続した多発関節炎とリウマチ因子の増加の後関節リウマチ（RA）で診断された2型糖尿病で、48歳の女性を報告する。
共有エピトープ（SE）-を含むヒト白血球抗原（HLA）-DRB1アレル（それはRAのための重要な疾病素質である）は、陽性だった。
RAは、素因的状態によりsitagliptinによって引き起こされたかもしれない。
